INTRODUCTION Inflammatory intestinal diseases are often accompanied with extraintestinal and even pulmonary manifesStations. The treatment of these intestinal diseases includes sulphasalazine and mesalazine, which may have undesirable allergic and other side effects, including hypersensitive pneumonitis. CASE REPORT Having performed colonoscopy due to abdominal pains and mushy stools, the dia...

We investigated the effect of DWac on the gut microbiota composition in mice with 2,3,6-trinitrobenzenesulfonic acid- (TNBS-) induced colitis. Treatment with DWac restored TNBS-disturbed gut microbiota composition and attenuated TNBS-induced colitis. Moreover, we examined the effect of DWac in mice with mesalazine-resistant colitis (MRC). Intrarectal injection of TNBS in MRC mice caused severe ...

......................................... Received: 17-10-13 Accepted: 19-12-13 Abstract MMX® mesalazine is an enteric formulation of 5-ASA with Multi Matrix technology for delayed and prolonged administration of high doses of mesalazine throughout the colon. Clinical trials have demonstrated its clinical and endoscopic efficacy for inducing remission. At doses of 2.4g to 4.8 g/day (2-4 tablets...

BACKGROUND High-dose (4.0 g/day) mesalazine is typically used for induction therapy, but its efficacy as maintenance therapy remains to be determined. We conducted a multicenter retrospective study to investigate the efficacy of continuous treatment with 4.0 g/day of mesalazine. MATERIAL/METHODS Japanese ulcerative colitis (UC) patients receiving acute induction therapy with 4.0 g/day mesalaz...

1 of 2 DESCRIPTION A 25-year old male with a 10-year history of ulcerative colitis (UC), maintained on clinical remission with mesalazine (1.5 g/day) presented with 1-week history of progressive fatigue and nausea. He had no other symptoms such as fever, arthralgia or skin rashes. He was found to be in renal failure with the following laboratory parameters: serum creatinine 13.9 mg/dl, urea 138...

BACKGROUND Maintenance therapy with 5-aminosalicylic acid (5-ASA) is a key strategy for preventing relapse in many patients with inflammatory bowel disease (IBD). Factors which disrupt 5-ASA delivery, such as non-adherence and 5-ASA switches, may destabilise symptom control. AIM To investigate the impact of non-adherence and medication switches on stable symptom control in UK patients with IB...

Oral mesalazine represents a crucial front-line agent for the treatment of active ulcerative colitis (UC) and the maintenance of remission. Clinical aspects of mesalazine therapy are guided by robust evidence-based guidelines, although there is a relative paucity of guidance examining the specific administrative and professional issues faced by inflammatory bowel disease (IBD) nurses. As IBD nu...

Mesalazine- (5-aminosalicylic acid-) containing products are a well-known treatment for inflammatory bowel disease, often as first line. Myocarditis is recognized as a very rare possible side effect of this drug treatment. We present a case of mesalazine-induced myopericarditis that was successfully improved by immediate cessation of the medication.

OBJECTIVE The aim of the study was to compare azathioprine versus mesalazine tablets for the prevention of clinical recurrence in patients with postoperative Crohn's disease (CD) with moderate or severe endoscopic recurrence. METHODS This was a 1 year, double-blind, double-dummy, randomised study which took place in 21 gastroenterology centres in Austria, the Czech Republic, Germany and Israe...

INTRODUCTION Mesalazine remains the first line treatment for the induction and the maintenance of remission in mild to moderate ulcerative colitis (UC). Its efficacy as a maintenance treatment after a first flare treated with corticosteroids has not been specifically studied. The aims of our work were to study a cohort of UC patients treated with mesalazine after a course of oral systemic corti...